BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 26439470)

  • 1. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
    Esposito S; Principi N;
    Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?
    Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M
    Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
    Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.
    Esposito S; Principi N
    J Immunol Res; 2015; 2015():591580. PubMed ID: 26351648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium.
    Wouters I; Desmet S; Van Heirstraeten L; Blaizot S; Verhaegen J; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2019 Feb; 37(8):1080-1086. PubMed ID: 30665775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
    Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
    J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.
    Cohen R; Biscardi S; Levy C
    Hum Vaccin Immunother; 2016; 12(2):277-84. PubMed ID: 26905678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
    Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
    BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N; Esposito S
    Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric radiologically confirmed community acquired pneumonia following PCV7 introduction in Switzerland.
    Chappuy H; Keitel K; Gehri M; Tabin R; Robitaille L; Raymond F; Corbeil J; Maspoli V; Bouazza N; Alcoba G; Lacroix L; Manzano S; Galetto-Lacour A; Gervaix A
    BMC Infect Dis; 2013 Jul; 13():357. PubMed ID: 23899390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.
    Allemann A; Frey PM; Brugger SD; Hilty M
    Vaccine; 2017 Apr; 35(15):1946-1953. PubMed ID: 28279564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era.
    Zuccotti G; Mameli C; Daprai L; Garlaschi ML; Dilillo D; Bedogni G; Faccini M; Gramegna M; Torresani E; ; Ballerini E; Benincaso A; Bonvissuto M; Bricalli D; Brioschi M; Calloni CS; Camiletti MI; Colella G; De Angelis L; Decarlis S; Di Nello F; Dozzi M; Galli E; Gandini V; Giuliani MG; Laviola F; Loda B; Macedoni M; Mazzucchi E; Metta MG; Moscatiello A; Nannini P; Petruzzi M; Picicco D; Picciotti M; Pisanelli S; Porta N; Ramponi G; Redaelli F; Rubini R; Sala N; Saitta V; Scelza G; Tiso RM; Tomasetto M; Torcoletti M; Travaini M; Valentini M; Vessia C
    Vaccine; 2014 Jan; 32(5):527-34. PubMed ID: 24342249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
    J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.